Literature DB >> 16622902

Interstitial pneumonitis associated with infliximab therapy.

Edith Villeneuve1, Anne St-Pierre, Boulos Haraoui.   

Abstract

Interstitial pneumonitis is a well documented, rare complication of methotrexate (MTX). We describe a patient with rheumatoid arthritis (RA) taking MTX for more than 3 years who then developed severe interstitial pneumonitis after a third infliximab infusion. Other similar cases are reviewed. Infliximab may potentiate pulmonary toxicity of MTX.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16622902

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


  12 in total

Review 1.  Bronchiolitis obliterans organizing pneumonia in patients with autoimmune rheumatic diseases.

Authors:  Carmen Maria Lara Rojas; Elisabetta Borella; Lavinia Palma; Silvio Ragozzino; Enrique De Ramón; Ricardo Gomez-Huelgas; Leonardo Punzi; Andrea Doria
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

2.  A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab.

Authors:  Shin-Ya Kawashiri; Atsushi Kawakami; Noriho Sakamoto; Yuji Ishimatsu; Katsumi Eguchi
Journal:  Rheumatol Int       Date:  2010-05-18       Impact factor: 2.631

Review 3.  Pulmonary manifestations of inflammatory bowel disease.

Authors:  Xiao-Qing Ji; Li-Xia Wang; De-Gan Lu
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

Review 4.  Pulmonary manifestations of Crohn's disease.

Authors:  De-Gan Lu; Xiao-Qing Ji; Xun Liu; Hong-Jia Li; Cai-Qing Zhang
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

Review 5.  Pathophysiological Concepts and Management of Pulmonary Manifestation of Pediatric Inflammatory Bowel Disease.

Authors:  Florian Schmid; Cho-Ming Chao; Jan Däbritz
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

Review 6.  Pulmonary complications of tumor necrosis factor-targeted therapy.

Authors:  Krishna Thavarajah; Peggy Wu; Elisa J Rhew; Anjana K Yeldandi; David W Kamp
Journal:  Respir Med       Date:  2009-02-07       Impact factor: 3.415

7.  Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment.

Authors:  Hirofumi Taki; Yukio Kawagishi; Koichiro Shinoda; Hiroyuki Hounoki; Reina Ogawa; Eiji Sugiyama; Kazuyuki Tobe
Journal:  Rheumatol Int       Date:  2009-12       Impact factor: 2.631

Review 8.  Noninfectious interstitial lung disease during infliximab therapy: case report and literature review.

Authors:  Roberta Caccaro; Edoardo Savarino; Renata D'Incà; Giacomo Carlo Sturniolo
Journal:  World J Gastroenterol       Date:  2013-08-28       Impact factor: 5.742

Review 9.  Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches.

Authors:  Osamu Matsuno
Journal:  Respir Res       Date:  2012-05-31

Review 10.  Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis.

Authors:  Shunsuke Mori
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2015-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.